Return to Clinical Trials Search Results

A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

Primary Outcome Measures: 1. Overal Survival [Time Frame: From date of study entry until the date of death from any cause (up to 5 years)] 2. Progression Free Survival (PFS) by RECIST 1.1 [Time Frame: From date of study entry until the death from any cause, or up to 5 years after last study treatment] Secondary Outcome Measures: 1. Combined CA-125 and RECIST 1.1 response (GCIG) [Time Frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment] 2. CA-125 Response (GCIG) [Time Frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment] 3. Objective response rate (ORR) or RECIST 1.1 [Time Frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment]

Primary Outcome Measures: 1. Overal Survival [Time Frame: From date of study entry until the date of death from any cause (up to 5 years)] 2. Progression Free Survival (PFS) by RECIST 1.1 [Time Frame: From date of study entry until the death from any cause, or up to 5 years after last study treatment] Secondary Outcome Measures: 1. Combined CA-125 and RECIST 1.1 response (GCIG) [Time Frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment] 2. CA-125 Response (GCIG) [Time Frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment] 3. Objective response rate (ORR) or RECIST 1.1 [Time Frame: From date of study entry until the date of death from any cause, or up to 5 years after last study treatment]